I move: "That the Bill be now read a Second Time."
This is an annual technical Bill regarding health insurance. However, there is a crucial difference this year in that I propose to make amendments to the Bill in the House in the coming hour or two which will create the legal framework for the provision of free hormone replacement therapy in Ireland for the first time. We are liberally using the legislative tools available to us.
Before we get to that, I must of course address the health insurance aspects of the Bill, namely concerning the risk equalisation scheme. Health insurance coverage stands at 47% of the population. This is 2.5 million people and represents a total annual premium income of €3.2 billion. Health insurance in Ireland is provided according to four principles: open enrolment, lifetime cover, minimum benefit and community rating. Unlike a risk-rated market, in a community-rated private health insurance market everyone pays the same price for a particular insurance policy. Insurers cannot take into account personal circumstances like health status or age. If they could, older and sicker people would have to pay a lot more for health insurance. The risk equalisation scheme is the mechanism designed to support our policy objective of a community-rated health insurance market. The stamp duty levies are collected by the Revenue Commissioners and transferred to the risk equalisation fund, which is administered by the Health Insurance Authority, HIA. The risk equalisation fund is designed to be Exchequer-neutral. The risk equalisation credits and stamp duty are updated on an annual basis. That is the main purpose of this annual Bill.
The HIA provided me with an annual report which analysed market data for the 12-month period from 1 July 2023 to 30 June 2024. This report recommended the risk equalisation credits, and the stamp duty levies required to fund them, to apply from 1 April next year. I have approved the risk equalisation credits to apply in 2025 and the Minister for Finance has approved the corresponding stamp duty levies. This year there will be no change to the hospital utilisation credit and the high-cost claim credit. The age-related health credit will increase for advanced policies and will decrease for most of the non-advanced policies.
In addition to the changes to the age-related health credits, this Bill will amend the definition of high-cost claims. High-cost claims arise in the Irish health insurance market where an insured person is extremely ill. They might attend hospital for an extended period. The claims are closely linked to very severe conditions and chronic conditions, such as cancer. The high-cost claims pool operates by compensating a portion - currently 45% - of a health insurance claim that exceeds a certain threshold. That threshold is currently €50,000 and applies within a calendar year. The remainder of the claim is covered by the insurer. The definition of a high-cost claim was to have included all HSE-approved drugs but it did not. An amendment to the definition, which is what we have here, is required to ensure the original broader policy intention is met.
I will now speak to the sections of this Bill. Section 1 defines the principal Act as the Health Insurance Act 1994.
Section 2 amends the definition of a high-cost claim to include a number of HSE-published lists of drugs and all drugs that are approved under the HSE drugs approval process. It also includes immunoglobulins, a group of drugs that were approved prior to the establishment of the current HSE drugs approval process in 2013. The revised definition will apply from the date of the introduction of the high-cost claim credit, 1 April 2022. This will ensure the State remains in compliance with the European Commission's approval of the risk equalisation scheme.
Section 3 amends section 11C of the principal Act to provide for 1 April 2025 as the effective date for revised credits payable from the risk equalisation fund.
Section 4 replaces table 2 in Schedule 4 to the principal Act. This table revises the applicable age-related health credits payable from the risk equalisation fund. The amounts are applicable on or after 1 April 2025. The amount of the credit depends on the person’s age and sex and on whether they have advanced or non-advanced cover. Non-advanced contracts provide for mostly public hospital cover, while advanced contracts provide a higher level of cover, including cover in private hospitals. Age-related health credits for advanced products will increase for all ages and genders. This is to meet the expected increase in claims in these segments of the market. Most of the age-related health credits will decrease for non-advanced products for all ages and genders. It is expected that there will be a reduction in claims for these segments of the market.
Section 5 amends section 125A of the Stamp Duties Consolidation Act 1999 to specify the applicable stamp duty rates to apply in the market for 2025. The stamp duty payable on non-advanced health insurance contracts will decrease from 1 April 2025. It will be €94 per adult, a decrease of €11 from the current rates, and €31 per child, a decrease of €4.
On advanced health insurance contracts, the stamp duty will increase to be €469 per adult, which is an increase of €49 from 2024 rates and €156 per child, an increase of €16.
Section 6 provides for the Short Title, commencement, collective citation and construction of the Bill.
The risk equalisation approach is supported by the public. According to a 2021 survey by the HIA, nearly 80% of those surveyed agreed that premium prices should not be dictated by a person’s current health. The same survey confirmed that more than 70% agreed that older people should not be charged more for health insurance.
The approach is in line with the Government’s work in reducing the costs of healthcare for people across the board. In the lifetime of this Government, we abolished inpatient hospital charges. There was a cost of up to €800 for an individual, which could be at a time when somebody was very sick and already dealing with a lot of different issues. We have rolled out free contraception up to the age of 35. We expanded access to free GP care to an extra 500,000 people, including children up to the age of eight. We introduced fully State-funded assisted human reproduction or free IVF. We reduced the drug payment threshold significantly to €80. That is the maximum amount any family would pay for medicines in any given month. We also fully paid for the costs of diagnostics where GPs are referring their patients - hundreds of thousands of patents - be it for X-ray, MRI, DXA, ultrasound or CT scans. These are now fully paid for by the State. Critically, those patients get to go back to the GP, so there is a benefit to the patient and the GPs are very happy that they do not lose their patients to an outpatient waiting list. They can bring their patients back and continue with their treatment of them. Most recently, I allocated funding for the provision of free HRT. I very much look forward to discussing that in more detail when I bring forward the Committee Stage amendments shortly.